Literature DB >> 2169457

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.

D A Revicki1, B R Luce, J M Weschler, R E Brown, M A Adler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169457     DOI: 10.1176/ps.41.8.850

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


× No keyword cloud information.
  20 in total

1.  Effects of capitation on health of the chronically ill. Implications for antipsychotic drug therapy.

Authors:  S K Reed; K Maharaj
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 2.  Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.

Authors:  M Drummond; J Menzin; G Oster
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

4.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

5.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 6.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

7.  Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Authors:  E T Edgell; S W Andersen; B M Johnstone; B Dulisse; D Revicki; A Breier
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

8.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

Review 9.  Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.

Authors:  Sandra L Tunis; Haya Ascher-Svanum; Michael Stensland; Bruce J Kinon
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 10.  Recent developments in the management of psychosis.

Authors:  M J Hoes
Journal:  Pharm World Sci       Date:  1998-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.